Last reviewed · How we verify
LY2196044
At a glance
| Generic name | LY2196044 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study for the Treatment of Alcohol Dependence (PHASE2)
- Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol Dependence (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2196044 CI brief — competitive landscape report
- LY2196044 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI